Ellagic acid
(Synonyms: 鞣花酸) 目录号 : GC15548
Ellagic acid是一种天然存在的多酚二内酯，广泛存在于多种水果和坚果中，可有效抑制CK2（IC50=40nM）和SHP2（Ki=20nM）的活性。
Cas No.:476-66-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ellagic acid is a naturally occurring polyphenolic dilactone widely found in various fruits and nuts, which effectively inhibits the activity of CK2 (IC50=40nM) and SHP2 (Ki=20nM)[1-2]. Ellagic acid demonstrates potential research value in multiple disease models, including anti-cancer, anti-inflammatory, antioxidant, liver protection, and neuroprotection[3-4].
In vitro, treatment of esophageal squamous cell carcinoma (ESCC) cells (EC9706 and KYSE450) with Ellagic acid (0-40μM) for 24-72 hours, Ellagic acid significantly inhibited cell survival and induced apoptosis in a concentration-dependent manner. Ellagic acid markedly promoted PARP cleavage, downregulated the expression of anti-apoptotic proteins Bcl-2 and Mcl-1, and upregulated SHP-1 expression to inhibit STAT3 signaling pathway activity[5]. Treatment of renal cell carcinoma (RCC) cells (786-O and ACHN) with Ellagic acid (50μM) for 24 hours, Ellagic acid significantly inhibited cell migration and invasion capabilities. Ellagic acid downregulated the expression of transcription factor RUNX2, thereby reducing the mRNA and protein levels of matrix metalloproteinase MMP1, thus inhibiting the metastatic potential of RCC cells[6].
In vivo, pretreatment of C57BL/6 mice with Ellagic acid (60mg/kg/day) via oral gavage for 14 consecutive days (followed by establishment of a hepatic ischemia-reperfusion model), Ellagic acid significantly inhibited caspase-1-GSDMD pathway-mediated pyroptosis, reduced serum ALT, AST, and LDH levels, decreased the expression of IL-1β and IL-18 in liver tissue, and alleviated pathological damage such as hepatic congestion and necrosis[7]. Treatment of STZ-induced diabetic ICR mice with Ellagic acid (100mg/kg/day) via oral gavage for 8 consecutive weeks, Ellagic acid significantly improved gastrocnemius muscle fiber cross-sectional area and grip strength, reduced serum CK, LDH, TC, TG, and LDL levels while increasing HDL, and alleviated muscle atrophy by inhibiting Atrogin-1/MuRF-1-mediated protein degradation, enhancing NRF-1/PGC-1α mitochondrial function, reducing CHOP/GRP-78 endoplasmic reticulum stress, and regulating the BAX/Bcl-2 apoptosis pathway[8].
References:
[1] Yoganathan S, Alagaratnam A, Acharekar N, et al. Ellagic Acid and Schisandrins: Natural Biaryl Polyphenols with Therapeutic Potential to Overcome Multidrug Resistance in Cancer. Cells. 2021 Feb 21;10(2):458.
[2] Zeb A. Ellagic acid in suppressing in vivo and in vitro oxidative stresses. Mol Cell Biochem. 2018 Nov;448(1-2):27-41.
[3] Zhu H, Yan Y, Jiang Y, et al. Ellagic Acid and Its Anti-Aging Effects on Central Nervous System. Int J Mol Sci. 2022 Sep 19;23(18):10937.
[4] Shakeri A, Zirak MR, Sahebkar A. Ellagic Acid: A Logical Lead for Drug Development? Curr Pharm Des. 2018;24(2):106-122.
[5] Xu YY, Wang WW, Huang J, et al. Ellagic acid induces esophageal squamous cell carcinoma cell apoptosis by modulating SHP-1/STAT3 signaling. Kaohsiung J Med Sci. 2020 Sep;36(9):699-704.
[6] Huang PY, Hung TW, Hsieh YH, et al. Ellagic acid suppresses the human renal carcinoma cell migration and invasion by targeting the RUNX2/MMP1 expression. Int J Med Sci. 2025 Apr 22;22(10):2308-2317.
[7] Wang H, Miao F, Ning D, et al. Ellagic acid Alleviates hepatic ischemia-reperfusion injury in C57 mice via the Caspase-1-GSDMD pathway. BMC Vet Res. 2022 Jun 18;18(1):229.
[8] Liu X, Cheng C, Deng B, et al. Ellagic acid attenuates muscle atrophy in STZ-induced diabetic mice. Physiol Res. 2022 Nov 28;71(5):631-641.
Ellagic acid是一种天然存在的多酚二内酯，广泛存在于多种水果和坚果中，可有效抑制CK2（IC50=40nM）和SHP2（Ki=20nM）的活性[1-2]。Ellagic acid对多种疾病模型展现出潜在的研究价值，包括抗癌、抗炎、抗氧化、肝保护及神经保护等[3-4]。
在体外，Ellagic acid（0-40μM）处理食管鳞状细胞癌（ESCC）细胞（EC9706和KYSE450）24-72小时，Ellagic acid以浓度依赖性方式显著抑制细胞存活并诱导细胞凋亡，Ellagic acid显著促进PARP裂解和下调凋亡蛋白Bcl-2、Mcl-1表达，上调SHP-1表达抑制STAT3信号通路活性[5]。Ellagic acid（50μM）处理肾细胞癌（RCC）细胞（786-O和ACHN）24小时，Ellagic acid显著抑制细胞迁移和侵袭能力，Ellagic acid通过下调转录因子RUNX2表达，进而降低基质金属蛋白酶MMP1的mRNA和蛋白水平，从而抑制RCC细胞的转移潜能[6]。
在体内，Ellagic acid（60mg/kg/天）经口灌胃预处理C57BL/6小鼠（连续14天，随后建立肝脏缺血再灌注模型），Ellagic acid显著抑制Caspase-1-GSDMD通路介导的细胞焦亡，降低血清ALT、AST、LDH水平及肝组织中IL-1β、IL-18的表达，并减轻肝组织充血和坏死病理损伤[7]。Ellagic acid（100mg/kg/天）经口灌胃处理STZ诱导的糖尿病ICR小鼠（连续8周），Ellagic acid显著改善腓肠肌纤维横截面积和握力，降低血清CK、LDH、TC、TG、LDL水平并提升HDL，同时通过抑制Atrogin-1/MuRF-1介导的蛋白降解、增强NRF-1/PGC-1α线粒体功能、减少CHOP/GRP-78内质网应激及调节BAX/Bcl-2凋亡通路缓解肌肉萎缩[8]。
| Cell experiment [1]: | |
Cell lines | Esophageal squamous cell carcinoma (ESCC) cell lines (Eca-109, TE-1, EC9706, KYSE70, KYSE450) |
Preparation Method | ESCC cells were cultured in RPMI 1640 medium with 10% FBS and 1% penicillin/streptomycin. Cells were treated with increasing concentrations of Ellagic acid (0-40μM) for 24–72 hours. |
Reaction Conditions | 0-40μM; 24–72 hours |
Applications | Ellagic acid significantly inhibited ESCC cell survival in a concentration- and time-dependent manner, while having minimal effects on normal esophageal epithelial cells. Ellagic acid promoted apoptosis by inducing PARP cleavage and downregulating anti-apoptotic proteins (Bcl-2, Mcl-1). |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | Mice were orally administered Ellagic acid (60mg/kg daily) for 14 days before undergoing hepatic ischemia-reperfusion injury (IRI) surgery. The IRI model involved 90 minutes of hepatic ischemia followed by 2–6 hours of reperfusion. |
Dosage form | 60mg/kg; oral gavage; 14 consecutive days |
Applications | Ellagic acid pretreatment ameliorated hepatic IRI by reducing serum ALT, AST, and LDH levels, attenuating histopathological damage, and suppressing pyroptosis via the caspase-1-GSDMD pathway. Ellagic acid inhibited caspase-1 activity, GSDMD cleavage, and pro-inflammatory cytokines (IL-1β, IL-18). |
References: | |
| Cas No. | 476-66-4 | SDF | |
| 别名 | 鞣花酸 | ||
| 化学名 | 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione | ||
| Canonical SMILES | OC1=C(O)C2=C3C(C(OC4=C3C(C(O2)=O)=CC(O)=C4O)=O)=C1 | ||
| 分子式 | C14H6O8 | 分子量 | 302.19 |
| 溶解度 | ≥ 3.78mg/mL in DMSO with gentle warming | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3092 mL | 16.5459 mL | 33.0918 mL |
| 5 mM | 661.8 μL | 3.3092 mL | 6.6184 mL |
| 10 mM | 330.9 μL | 1.6546 mL | 3.3092 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet